We are live on ! Find out more
BSTC

BioSpecifics Technologies Corp.
BSTC

Delisted

BSTC was delisted on the 1st of December, 2020.

78 hedge funds and large institutions have $185M invested in BioSpecifics Technologies Corp. in 2018 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 31 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more capital invested

Capital invested by funds: $176M → $185M (+$9.37M)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

10% less repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 31

11% less funds holding

Funds holding: 8878 (-10)

53% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 17

Holders
78
Holders Change
-10
Holders Change %
-11.36%
% of All Funds
1.79%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.05%
New
8
Increased
28
Reduced
31
Closed
17
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
FQ
51
First Quadrant
California
$298K -$206K -4,916 -42%
SGAM
52
Smith Group Asset Management
Texas
$271K -$8.36K -199 -3%
Bank of Montreal
53
Bank of Montreal
Ontario, Canada
$240K +$2.31K +55 +1%
STA
54
Summit Trail Advisors
New York
$234K +$25K +596 +9%
GCP
55
GSA Capital Partners
United Kingdom
$222K -$92.4K -2,200 -31%
RhumbLine Advisers
56
RhumbLine Advisers
Massachusetts
$221K -$7.35K -175 -3%
Los Angeles Capital Management
57
Los Angeles Capital Management
California
$215K
Manulife (Manufacturers Life Insurance)
58
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$215K +$4.91K +117 +2%
Balyasny Asset Management
59
Balyasny Asset Management
Illinois
$204K +$193K +4,604 New
UBS Group
60
UBS Group
Switzerland
$197K -$50.7K -1,208 -21%
GC
61
Globeflex Capital
California
$191K -$1.01K -24 -0.6%
AIG
62
American International Group
New York
$160K -$8.19K -195 -5%
US Bancorp
63
US Bancorp
Minnesota
$110K -$17.9K -426 -15%
Citigroup
64
Citigroup
New York
$94K -$3.36K -80 -4%
Ohio Public Employees Retirement System (OPERS)
65
Ohio Public Employees Retirement System (OPERS)
Ohio
$57K -$63K -1,500 -54%
Barclays
66
Barclays
United Kingdom
$52K +$11.9K +284 +32%
BNP Paribas Financial Markets
67
BNP Paribas Financial Markets
France
$51.7K +$2.56K +61 +6%
JP Morgan Chase
68
JP Morgan Chase
New York
$50K -$3.4K -81 -7%
MAM
69
Meeder Asset Management
Ohio
$44K +$21K +501 +103%
Legal & General Group
70
Legal & General Group
United Kingdom
$41K -$19.5K -464 -33%
Bank of America
71
Bank of America
North Carolina
$32K -$12.3K -294 -29%
AIP
72
Ameritas Investment Partners
Nebraska
$22K
FANJ
73
Financial Architects (New Jersey)
New Jersey
$16K
Federated Hermes
74
Federated Hermes
Pennsylvania
$14K +$12.9K +306 New
AF
75
Allworth Financial
California
$9K

BSTC Hedge Fund Activity: Q1 2018 in Review

78 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in BioSpecifics Technologies Corp. (BSTC) for Q1 2018, worth a combined $185M — up 5.3% from $176M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of BSTC and 8 opened new positions — a net loss of 9 holders — while 31 trimmed existing stakes and 28 added.

The largest buyer was Stonepine Capital Management, adding an estimated $8.57M. The largest seller was Northpointe Capital, exiting entirely with an estimated $3.5M sold.

  • 78 institutional investors held BioSpecifics Technologies Corp. (BSTC) as of Q1 2018, down from 88 in Q4 2017.
  • Funds reported $185M of BioSpecifics Technologies Corp. stock for Q1 2018, up 5.3% quarter-over-quarter.
  • 8 funds opened new BioSpecifics Technologies Corp. positions in Q1 2018 and 17 closed out, a net change of -9 holders.
  • The largest BioSpecifics Technologies Corp. buyer in Q1 2018 was Stonepine Capital Management, an estimated $8.57M added.
  • The largest BioSpecifics Technologies Corp. seller in Q1 2018 was Northpointe Capital, an estimated $3.5M sold.

Based on aggregated 13F filings for Q1 2018.